RecruitingRecruiting
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
NCT07384897 · Université Catholique de Louvain
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.
Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.
The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Eligibility criteria
Inclusion Criteria:
* Diagnosis of lung cancer
* Presence of precancerous lung lesions
* Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment
* Control group: individuals without known lung disease
* Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
* Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected
Exclusion Criteria:
* Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent)
* Acute infection at the time of inclusion
* Refusal or inability to provide informed consent (or assent, when applicable)
* Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Study design
Enrollment target: 425 participants
Allocation: non_randomized
Masking: none
Age groups: child, adult, older_adult
Timeline
Starts: 2025-02-17
Estimated completion: 2032-02-17
Last updated: 2026-02-03
Interventions
Other: Peripheral Blood Collection for Immune Profiling
Primary outcomes
- • Progression free survival (Throughout the entire study, approximately during 7 years)
Sponsor
Université Catholique de Louvain · other
Contacts & investigators
ContactFrank Aboubakar Nana, MD; PhD · contact · frank.aboubakar@saintluc.uclouvain.be · 0032 2 764 85 19
ContactKim Henquin, Study nurse · contact · kim.henquin@saintluc.uclouvain.be · 0032 2 764 42 26
InvestigatorFrank Aboubakar Nana, MD; PhD · study_director, Cliniques universistaires saint Luc
All locations (1)
Cliniques universitaires saint LucRecruiting
Brussels, Belgium